Clinical trial
A Phase I Study of Safety and Pharmacological Activity of Substance P (sP) in the Reversal of Recent-Onset Type 1 Diabetes (T1D)
NCT02820558 is registered in ClinicalTrials.gov with Vanilloid Genetics Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase I Study of Safety and Pharmacological Activity of Substance P (sP) in the Reversal of Recent-Onset Type 1 Diabetes (T1D)
- Lead sponsor
- Vanilloid Genetics Inc.
- Phase
- Phase 1
- Overall status
- Unknown status
- Start date
- May 31, 2016
- Completion date
- December 31, 2022
- Enrollment
- 12 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.